Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Sanofi Taps Adagene's 'Masking' Tech In Over $2.5B Immuno-Oncology Pact

  • Sanofi SA (NASDAQ:SNY) has signed a collaboration with Adagene Inc (NASDAQ:ADAG) to advance two preclinical immuno-oncology candidates and an option to develop two more. 
  • Sanofi is paying $17.5 million upfront and promising up to $2.5 billion in potential milestones.
  • Under the terms of the agreement, Adagene will be responsible for early-stage research activities to develop masked versions of Sanofi candidate antibodies using Adagene's SAFEbody technology. 
  • Also See: Adagene's Posts Early Safety, Efficacy Data From Cold Tumors Trial.
  • Sanofi will be solely responsible for later-stage research and all clinical, product development, and commercialization activities.
  • SAFEbody technology uses precision masking to shield the binding domain of the biologic therapy. Activating the tumor microenvironment allows for tumor-specific targeting of antibodies while minimizing on-target off-tumor toxicity in healthy tissues. 
  • Price Action: ADAG shares are up 8.36% at $5.96, while SNY stock is down 0.67% at $50.72 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.